Background: Immune checkpoint (ICK) expression might represent a surrogate measure of tumor-infiltrating T cell (CTL) exhaustion and therefore be a more accurate prognostic biomarker for colorectal cancer (CRC) patients than CTL enumeration as measured by the Immunoscore. Methods: The expression of ICKs, Th1, CTLs, cytotoxicity-related genes, and metagenes, including Immunoscore-like metagenes, were evaluated in three independent cohorts of CRC samples (260 microsatellite instable [MSI], 971 non-MSI). Their associations with patient survival were analyzed by Cox models, taking into account the microsatellite instability (MSI) status and affiliation with various Consensus Molecular Subgroups (CMS). PD-L1 and CD8 expression were examined on a subset of tumors with immunohistochemistry. All statistical tests were two-sided. Results: The expression of Immunoscore-like metagenes was statistically significantly associated with improved outcome in non-MSI tumors displaying low levels of both CTLs and immune checkpoints (ICKs; CMS2 and CMS3; hazard ratio [HR] ¼ 0.63, 95% confidence interval [CI] ¼ 0.43 to 0.92, P ¼ .02; and HR ¼ 0.55, 95% CI ¼ 0.34 to 0.90, P ¼ .02, respectively), but clearly had no prognostic relevance in CRCs displaying higher levels of CTLs and ICKs (CMS1 and CMS4; HR ¼ 0.46, 95% CI ¼ 0.10 to 2.10, P ¼ .32; and HR ¼ 1.13, 95% CI ¼ 0.79 to 1.63, P ¼ .50, respectively), including MSI tumors. ICK metagene expression was statistically significantly associated with worse prognosis independent of tumor staging in MSI tumors (HR ¼ 3.46, 95%
CI ¼ 1.41 to 8.49, P ¼ .007). ICK expression had a negative impact on the proliferation of infiltrating CD8 T cells in MSI neoplasms (median ¼ 0.56 in ICK low vs median ¼ 0.34 in ICK high, P ¼ .004). Conclusions: ICK expression cancels the prognostic relevance of CTLs in highly immunogenic colon tumors and predicts a poor outcome in MSI CRC patients.
The host immune response, and especially the T cell immune infiltrate, intersects the molecular and clinical characteristics of primary colorectal cancers (CRCs), including TNM staging. It is associated with prognosis of localized colon tumors. Expression levels for CTL/Th1/cytotoxicity markers have been demonstrated to constitute strong and independent prognostic indicators in CRC patients, with a high density of lymphocyte infiltration being consistently associated with prolonged survival (1) . Based on multiple analyses, a scoring system was developed (termed Immunoscore) to quantify cytotoxic and memory T cells in the core of the tumor and in the tumor's invasive margin (2) . Immunoscore is a prognostic index in CRC (3) . Several authors have suggested that the dense Th1/CTL lymphocytic infiltrate could explain the better prognosis of colon tumors displaying microsatellite instability (MSI), compared with non-MSI (MSS) CRC (4) (5) (6) . MSI (7) (8) (9) (10) (11) (12) leads to the synthesis of aberrant and potentially immunogenic neo-antigens by the tumor cells (for review, see [13, 14] ). A likely consequence of this is that MSI tumors are heavily infiltrated with activated cytotoxic T-cell lymphocytes (CTLs) and Th1 cells.
A recent study reported that concomitant expression of multiple active immune checkpoint (ICK) markers (eg, CTLA-4, PD-1, PD-L1, LAG-3 targeted by immunotherapy) in CRC may counterbalance the antitumoral Th1/CTL immune response, notably in MSI CRC (15) . One hypothesis that stems from these observations is that MSI tumors would be more responsive to ICK inhibitors because ICK expression is expected to protect highly immunogenic tumor cells from being destroyed. In line with this hypothesis, Le et al. (16) evaluated the clinical activity of an anti-PD-1 ICK inhibitor (pembrolizumab) in a cohort of metastatic CRC patients with MSS and MSI primary tumors. The results of this phase II study showed that MSI status was predictive of clinical benefit from ICK blockade therapy with pembrolizumab. The second hypothesis is that ICK expression should exert a negative impact on the prognosis of MSI tumors untreated by ICK inhibitors. To our knowledge, this second hypothesis has not yet been assessed thoroughly. It was reported in a recent study that the Immunoscore was prognostic in MSI CRC (17) , but the authors did not integrate ICK markers in their survival analyses. Their results were obtained by investigating a unique series of CRC, and no further validation using publicly available clinical data was performed because the Immunoscore requires direct access to primary tumor samples. In other publications, only the role of PD1/PDL1 expression in CRC has been explored, leading to various conclusions and thus demonstrating the complexity involved with analysis of the CRC immune response (18) (19) (20) (21) .
Rather than analyzing CRC immune response through the expression of PD1/PDL1 or T cell enumeration, our aim here was for a more holistic assessment of T cell immune response quality based on the analysis of both Th1/CTL and ICK markers. We also took into account the major molecular subtypes of CRC, that is, MSI/MSS status and consensus molecular subtypes (CMS) (22) . Finally, the functional relevance of ICK overexpression was determined by pathway enrichment analysis and by quantification of immune infiltrates and CD8 T cell proliferation in MSI tumors.
Methods

Immune Genes
Immune checkpoint and modulator genes were selected according to Llosa et al. (15) and a recent review (23) . Markers for cytotoxic T lymphocytes, cytotoxicity, and T helper1 were selected as described earlier (see also the Supplementary Materials and Methods, available online) (15, 24) .
Cohort Data
Tissue samples from a large multisite cohort of CRC patients were collected as part of the "Cartes d'Identité des Tumeurs" (CIT) research program/enlever network, including tumors with or without microsatellite instability (MSI or MSS, respectively) and adjacent nontumoral tissue samples (NT). Samples from 146 MSI tumors, 444 MSS tumors, and 56 NT were analyzed for gene expression profiles on Affymetrix U133 plus 2 chips as described earlier (25) . Data were normalized using the frozen RMA method (26) followed by Combat normalization (27) to remove technical batch effects (SVA R package). In addition, the CRC cohort from the The Cancer Genome Atlas (TCGA) consortium was also used (86 MSI tumors, 527 MSS tumors, 51 NT). Both data sets were centered for each gene by subtracting the median value of the non-tumoral sample and are provided as a Supplementary Data File (available online).
An additional retrospective, multisite series of 28 stage IV primary MSI CRCs was analyzed separately for gene expression as part of an independent, ongoing study using the NanoString nCounter platform. A set of immune genes that comprised 14 of the 32 analyzed markers, including seven ICKs, was screened. All patients from this metastatic cohort (11 synchronous metastatic lesions, 17 metachronous metastatic lesions) received standard of care chemotherapy but not ICK blockade treatment. The NanoString data set also includes a subset of the CIT cohort samples for which sufficient RNA material was available for analysis (for protocol details, see the Supplementary Materials and Methods, available online).
Supplementary Table 1 (available online) gives a description of all the cohorts investigated in this study, totaling 260 MSIs and 971 MSS CRCs. For non-metastatic MSI CRC patients, informed consent was recorded in each case; the standard hospital blanket consent was considered sufficient by French law. For patients included in the cohort of metastatic CRCs, ethical approval was provided by an institutional review board (institutional review board No. 00003835) on November 27, 2014.
chi-square tests. MSigDB gene sets/pathways enrichment analysis was performed by comparing low-and high-ICK groups, using the hypergeometric test and based on the genes most statistically significantly differentially expressed between these two groups. Associations between gene /metagene expression values and survival in the different cohorts were assessed by univariate and bivariate Cox proportional-hazards regression analyses and adjusted by tumor series and TNM stage, using the R package "survival," and the results were combined using a generic inverse variance meta-analysis approach (see also the Supplementary Materials and Methods, available online). The proportional-hazards assumption was tested prior to survival analysis to examine the models' appropriateness using the cox.zph function. Survival curves were obtained using KaplanMeier estimates, and differences between curves were assessed using the log-rank test. Overall survival was used and defined as time from diagnosis to death from any cause. All statistical tests were two-sided. The cut point for statistical significance was .05.
Results
Prognostic Value of Immune Genes and Metagenes in Function of CMS Classification of Colorectal Cancer
To test our working hypothesis, summarized in Figure 1A , we evaluated the prognostic significance of ICKs, Th1, CTLs, and cytotoxicity markers in the combined CIT (n ¼ 590 CRC, comprising 146 MSI and 444 MSS) and TCGA (n ¼ 613 CRC, comprising 86 MSI and 527 MSS) series. In both cohorts, MSS tumors were categorized into one of the four CMS subtypes of CRC (22) . We investigated 32 immune markers classified into the above four immune marker groups (see the Supplementary Materials and Methods, available online, for a list of these markers) (for review, see [24] ) as independent genes and as four metagenes. Four of the 19 immune checkpoints and modulators were not statistically significantly overexpressed in CRC as compared with nontumor colonic mucosa and were subsequently removed (Supplementary Figure 1 , available online). Further analyses were thus carried out on the 28 remaining genes. Finally, to obtain Immunoscore surrogates, six Immunoscore-like metagenes were built based on the expression of Immunoscorerelated markers (Supplementary Table 2 , available online).
As a preliminary step, the prognostic values of MSI and CMS status were confirmed with, as expected, an improved prognosis for patients with MSI CRCs, compared with those with MSS CRCs, and a statistically significant prognostic value of the CMS classification ( Figure 1B In univariate models, the overexpression of CTL/Th1/cytotoxicity/Immunoscore markers and metagenes was also associated with adverse prognosis in MSI CRC (Figure 1 , C and E; Supplementary Figure 3 , A and B, available online). We therefore hypothesized that high expression levels of ICKs in MSI CRC could counterbalance and mask the expected positive effect of CTL/Th1/cytotoxic cells or Immunoscore-related cells on prognosis. Bivariate Cox models at the metagene level were consistent with this assumption ( Figure 1F ). All together, these data underline that ICKs and Immunoscore biomarkers constitute an independent prognostic factor for overall survival in MSI and MSS tumors, respectively.
Expression and Prognostic Value of Immune Checkpoints in an Independent Metastatic MSI CRC Patient Series
The CIT and TCGA series included mostly non-metastatic MSI CRC patients (n ¼ 220/232, 94.8%). Because ICK blockade was recently proposed as a promising new therapy for metastatic MSI CRC, we endeavored to further evaluate the prognostic relevance of ICK expression in an additional retrospective, multisite series of 28 stage IV primary MSI CRCs treated with standard care that were analyzed separately for gene expression as part of an independent, ongoing study using the NanoString nCounter platform. To do this, we analyzed the expression of the seven ICKs that were previously screened (CD274, PDCD1LG2, HAVCR2, LAG3, ICOS, CTLA4, PDCD1).
As with non-metastatic MSI colon tumors, we observed statistically significant association of PD-L1 (CD274) expression with worse OS and worse survival after relapse (SAR) (Figure 2A ). Associations of TIM-3 (HAVCR2) and LAG3 expression, although not statistically significant, were suggested. Again, the overexpression of metagenes corresponding to CTL/ Th1/cytotoxicity/Immunoscore markers (CTL ¼ CD3D, CD3G, CD8A, PTPRC; CYTOX ¼ GNLY, GZMK; Th1¼ IFNG) tended to associate with adverse prognosis in univariate models ( Figure 2B ). However, in bivariate Cox models, the expression of CTL/Th1/ cytotoxicity/Immunoscore-related metagenes was associated with good prognosis (hazard ratio [HR] < 1.00), as expected ( Figure 2C ). Several ICK markers, in particular the druggable PD-L1 (CD274) and TIM-3 (HAVCR2) molecules (23) , are therefore likely to constitute biomarkers for poor prognosis in both metastatic and non-metastatic MSI CRC patients.
Immune Checkpoint Gene Expression Distribution in Colorectal Cancer
We next investigated the level of variation in ICK expression among CRC tumors in order to further assess their relevance as prognostic and theranostic markers. ICK expression was analyzed in stage I through IV CRC and in nontumor colonic mucosa from our CIT cohort (590 CRC, 56 NT) and in the TCGA cohort (613 CRC, 51 NT). In both cohorts, the metagenes corresponding to ICKs, CTL, cytotoxicity, and Th1 orientation were overexpressed in MSI and in MSS tumors belonging to CMS1 and CMS4, as compared with MSS CRCs from CMS2 and CMS3 ( Figure 3A ). Each cell also contains the P value for the Wald test for equality of this hazard ratio to 1. The hazard ratio shown in each cell was calculated by combining the hazard ratios for each of the CIT and TCGA data sets using the meta-analysis approach of DerSimonian.
The genes relevant to each metagene are indicated in (C) (ICK, CTL, CYTOX, TH1) or are given below the metagene name. 
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in all CMS subtypes in both cohorts ( Figure 3B) . A high degree of heterogeneity was observed in CMS1 tumors ( Figure 3B ), particularly in MSI tumors, where high to very high expression levels of ICKs were observed in a large proportion of cases ( Figure 3B ). Expression levels for all of the 28 immune markers were highly correlated in the MSI CRCs from both cohorts ( Figure 3C ). The present results highlight the extent of heterogeneity of MSI CRC with respect to immunity and to the overexpression of ICK molecules. This was observed regardless of MSI CRC origin (inherited or sporadic) or of other clinical or molecular parameters such as sex, tumor location, tumor stage, CMS, or KRAS/ BRAF mutations (Supplementary Figure 4 , available online). Considerable variation in the expression of ICK markers was also observed in the independent metastatic MSI CRC series evaluated by NanoString ( Figure 3D ).
Functional Relevance of Immune Checkpoint Expression in CRC
We next addressed the possible physiological relevance of ICK overexpression in CRC. Tumor infiltration by immune cells was quantified using MCP counter software (28) expression ( Figure 4A ). These results suggest that ICK expression occurs in response to an efficient in situ adaptive T cell immune response. Pathway enrichment analysis was performed to compare the expression profiles of MSI tumors with low vs high ICK expression levels. Statistically significant associations were observed between ICK expression and immune response gene sets, including positive activation of T cell response, negative regulation of T cell activation, T cell exhaustion, IL-10 response, and chronic viral infection (29) (Figure 4B ). Hence, we conclude that there is a strong correlation between ICK expression and the presence of an exhausted T cell immune response in MSI CRC.
To further investigate the functional relevance of ICKs in MSI tumors, we studied eight primary MSI tumors showing upregulation of ICKs and 12 without. PD-L1 and CD8 expression were examined using immunohistochemistry (IHC). PD-L1 expression was observed only in the tumor bed, whereas CD8 was present both in the tumor core and in stromal areas ( Figure 4C ). Moreover, PD-L1 expression correlated strongly with ICK expression (Supplementary Figure 5 , available online), while we observed concomitant increases of CD8 infiltrates in both the tumor bed and in the peritumoral stroma with PD-L1 IHC staining ( Figure 4D CD276  TNFRSF9  IDO1  CD274  ICOS  CTLA4  TNFRSF4  VTCN1  CD40  TNFRSF18  HAVCR2  PDCD1LG2  LAG3  PDCD1  IL2RB  BTLA  CD28  CD27  C10orf54   CD276  TNFRSF9  IDO1  CD274  ICOS  CTLA4  TNFRSF4  VTCN1  CD40  TNFRSF18  HAVCR2  PDCD1LG2  LAG3  PDCD1  IL2RB  BTLA  CD28 VTCN1  CD276  PDCD1  TNFRSF4  TNFRSF18   CD40  CD274  CTLA4  ICOS  IDO1  TNFRSF9  HAVCR2  PDCD1LG2   IL2RB  LAG3  PTPRC  CD3G  CD8A  CD3D  CD3E  GZMK  GZMB  GNLY  GZMA  PRF1  GZMH  TBX21 . P values were calculated using a Student's t test. P values were calculated using a Student's t test to assess the statistical significance of differences between MSI and NT and between MSI and MSS/CMS (***P < .001, **P < .01, *P < . 
Discussion
During cancer progression, tumor-infiltrating T cells have been shown to display increased chronic expression of different antagonist ICKs, causing functional exhaustion and unresponsiveness of T cells (30) . The exhausted CD8 T cells fail to proliferate in response to antigen and lack critical anticancer effector functions (31) . Checkpoint inhibitors could boost the anticancer immune response, and the potential relevance of these inhibitors for the treatment of metastatic MSI CRC patients was highlighted (16) . In the present study, we showed that ICK overexpression represents a more accurate prognostic biomarker for MSI CRC patients treated with standard care than the classical assessment of T cell number by Immunoscore (1). This may be explained by the presence of exhausted nonproliferative CD8 T cells in the core of these neoplasms. More generally, our data indicate that assessment of the prognostic significance of antitumor immunity in CRC needs to take into account ICK expression. This is particularly relevant for colon tumors displaying immunogenic profiles with both high Immunoscores and ICK expression, such as in MSI tumors and probably a substantial proportion of MSS CRCs.
The current results were obtained using univariate Cox models for survival analysis and a transcriptome-based method to quantify both ICK and CTL/Th1/cytotoxicity (Immunoscore) markers. We validated our method by building Immunoscorelike surrogates that were associated with statistically significantly improved survival of CRC patients. Under the same conditions, the CTL/Th1/cytotoxicity and Immunoscore markers were both associated with worse prognostic in MSI CRC. These results are potentially in conflict with a recent publication that observed a statistically significant association between Immunoscore and improved outcome in a single series of 105 MSI CRC patients (17) . Although the studies are not directly comparable, here we assessed three independent cohorts of CRC patients, totaling more than 1200 cases and including 260 MSI CRCs. However, it does not include classical Immunoscore evaluation by immunohistochemistry.
Bivariate Cox analysis, combining ICK metagene with CTL or Th1 or cytotoxicity or Immunoscore-like metagene, revealed that expression of metagenes related to CTL/Th1/cytotoxicity and Immunoscore markers was associated with trends for better prognosis in MSI CRC from both the CIT and NanoString metastatic series, whereas the ICK metagene was statistically significantly associated with worse prognosis. However, this association was not observed in the TCGA cohort as it had too few events (n ¼ 5) to get sufficient statistical power. Therefore, validation in another larger cohort is required. In contrast with the earlier study that focused only on the PD1/PDL1 couple (17), a more global assessment of ICK gene expression in the tumor core, as proposed in the present study, allows a more holistic view of the T cell immune response in CRC. Moreover, the transcriptome-based method reported here is easier to use and more amenable to standardization. It can be also used to test publicly available clinical data sets, whereas this is not possible with Immunoscore because of the need to assess primary tumor samples.
Recent clinical trials have demonstrated that antibodies targeting PD-1 or PD-L1 can induce a major response in many types of cancers (32) . The overall survival rate with more than five years' follow-up for stage II and III MSI CRC patients is approximately 70% without adjuvant chemotherapy and 75% to 90% with standard care adjuvant chemotherapy (33) (34) (35) , whereas it is less than 5% for stage IV MSI CRC patients. We report here for the first time the prognostic significance of ICK overexpression in both metastatic and nonmetastatic MSI CRC and in the absence of immunotherapy. These findings should help to better inform the prognosis of MSI CRC patients. They may be useful for guiding future immunotherapy involving antibody blockade of ICKs in nonmetastatic MSI CRC patients and for having predictive factors of immunotherapy efficacy for patients with metastatic disease.
The limitations of our study are mainly related to the fact that it is not yet ready for routine clinical use. First, it will be necessary to confirm in large and prospective series of patients from randomized trials that the outcome of CRC patients is determined by the CTL/ICK balance. Second, it will be necessary to further assess the prognostic relevance of combined ICK and CTL marker expression in MSI CRC. This should allow patients who are at high risk of relapse to be identified and thus indicated for more intensive treatments linked to these molecular markers. Such work will help to confirm ICK molecules as clinically relevant theranostic factors for the treatment of MSI CRC.
To conclude, our results highlight the extent of heterogeneity of CRC with respect to immunity, and the overexpression of ICK molecules in particular. They suggest that prediction of CRC patient outcomes through evaluation of immune components in the tumor microenvironment will likely be improved by the 
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integration of ICK markers, the prognosis of colon tumors being determined by the CTL/ICK balance ( Figure 5 ). More particularly, our results indicate that ICK expression impacts the prognosis of MSI tumors. To inform future immunotherapy involving antibody blockade of ICKs and resistance to these molecules in MSI CRC patients, additional studies on the molecular mechanisms underlying the immune reaction against MSI tumor cells are required, for example, the number and type of MSI-driven mutational events that drive the synthesis of aberrant, immunogenic peptides (36) . Identifying these somatic events with respect to quantitative and qualitative antitumoral immunity may improve the personalized treatment of MSI CRC patients with ICK inhibitors, in both metastatic and nonmetastatic settings.
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